Red Blood Cell – IMProving trAnsfusions for Chronically Transfused Recipients (RBC-IMPACT)

About the study

Red Blood Cell – IMProving trAnsfusions for Chronically Transfused recipients (RBC-IMPACT) is an observational cohort study to assess donor, component, and recipient factors that contribute to RBC efficacy in chronically and episodically transfused patients. The objective of the study is to determine how specific genetic and non-genetic factors in donors and recipients may impact RBC survival after transfusion – in short, what factors on both the donor and recipient side may improve the efficacy of the transfusion.

Study point of contact

Kathy Chapman, MT
[email protected]
Sunitha Mathew, MPH
[email protected]



Study type






participation requirements

(Aim #1):

Well-characterized transfusion-dependent form of SCD or thalassemia (including Hemoglobin E-thalassemia and sickle-beta thalassemia) on chronic simple transfusion therapy
On a regular simple RBC transfusion schedule (i.e., 1-3 units scheduled every 2-6 weeks and on a minimum 6-month chronic transfusion trial)
Seen at any participating domestic hub hospital (i.e., Columbia University Irving Medical Center/Morgan Stanley Children’s Hospital of New York, Weill Cornell Medical Center/Komansky Children’s Hospital, Boston Children’s Hospital, Froedtert & Medical College of Wisconsin/Children’s Wisconsin, University of California San Francisco, Benioff Children’s Hospital Oakland) or enrolled in the Brazil REDS-IV-P sickle cell disease cohort and seen at any participating Brazil hemocenter (i.e., Childrens Institute and Adult Clinics at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo – HCFMUSP, HEMOAM – Amazonas, HEMOMINAS – Minas Gerais, HEMOPE -Pernambuco, and HEMORIO – Rio de Janeiro)

participation restrictions

(Aim #1):

Institutionalization or imprisonment
Foster care

Last updated 2022-03-18